Abstract |
Alzheimer's disease (AD) is rapidly grooving incidence that affects millions of people worldwide, therefore there is an immediate need for its' early and accurate diagnosis. Many research studies have been performed on possible accurate and reliable diagnostic biomarkers of AD. This review study provides an overview on the cerebrospinal fluid (CSF) proteins that are used as biochemical markers for the early diagnosis of AD and their future prospects, as well as relevant patents.
|
Authors | Vasileios T Papaliagkas, Magda Tsolaki, George Anogianakis |
Journal | Recent patents on CNS drug discovery
(Recent Pat CNS Drug Discov)
Vol. 5
Issue 2
Pg. 172-8
(Jun 2010)
ISSN: 2212-3954 [Electronic] United Arab Emirates |
PMID | 20408808
(Publication Type: Journal Article, Review)
|
Chemical References |
- Amyloid beta-Peptides
- Biomarkers
- Brain-Derived Neurotrophic Factor
- Cerebrospinal Fluid Proteins
- Inflammation Mediators
- Isoprostanes
- Metals
- Peptide Fragments
- amyloid beta-protein (1-42)
- tau Proteins
- Cytochromes c
- Amyloid Precursor Protein Secretases
|
Topics |
- Alzheimer Disease
(cerebrospinal fluid, diagnosis)
- Amyloid Precursor Protein Secretases
(cerebrospinal fluid)
- Amyloid beta-Peptides
(cerebrospinal fluid)
- Biomarkers
(cerebrospinal fluid)
- Brain-Derived Neurotrophic Factor
(cerebrospinal fluid)
- Cerebrospinal Fluid Proteins
(cerebrospinal fluid)
- Cognition Disorders
(cerebrospinal fluid)
- Cytochromes c
(cerebrospinal fluid)
- Humans
- Inflammation Mediators
(cerebrospinal fluid)
- Isoprostanes
(cerebrospinal fluid)
- Metals
(cerebrospinal fluid)
- Molecular Structure
- Patents as Topic
- Peptide Fragments
(cerebrospinal fluid)
- tau Proteins
(cerebrospinal fluid)
|